Presenter: C. Louvet Affiliation: Hospital St-Antoine, Paris France
Gemcitabine has been shown to be an active agent in the treatment of pancreatic cancer. Some preclinical data showed that the combination of gemcitabine with oxaliplatin (GEMOX) exerts potent antiproliferative effects in human cancer cell lines, including colon cancer.
Materials and Methods:
A total of 64 patients with advanced pancreatic carcinoma (APC) were included in this phase II study.
Patients received the GEMOX every 2 weeks for 6 cycles followed by chemoradiation.
Oxaliplatin dose was 100 mg/m2 with 2 hour indusion and gemcitabine was given 1000 mg/m2 every 2 weeks.
Chemoradiaiton with 5-FU was used in patients with stage II/III diseases.
19 patients achieved partial remission, 28 stable disease, and 16 progression of disease
Median progression-free survival was 21 weeks.
6-month survival was 71%.
Treatment was well tolerated.
Neutropenia, thrombodytopenia, and nausea and vomiting were the common toxicities.
GEMOX appeared to be active and well tolerated in patients with APC.
The remarkable low toxicity is of major value in this palliative situation.
This regimen will be tested in a phase III randomized study comparing GEMOX versus gemcitabine alone.
Jul 18, 2012 - For most patients with locally advanced pancreatic carcinoma (LAPC), induction with a combination of gemcitabine and oxaliplatin (GEMOX) followed by chemoradiotherapy (CRT) is feasible, resulting in clinical benefit, a chance of resectability, and improved survival, according to a study published online July 6 in Cancer.